Today: 20 May 2026
Browse Category

NASDAQ:ABVX 20 November 2025 - 7 January 2026

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··

Stock Market Today

  • UiPath Shares Dip Amid Microsoft Korea Collaboration and Cloud Automation Expansion
    May 19, 2026, 7:30 PM EDT. UiPath (PATH) shares fell 0.99% to $10.54 on heightened trading volume following a collaboration with Microsoft Korea to launch Automation Cloud locally, aiming to boost regional cloud automation adoption. The initiative offers Korean enterprises local data residency support, crucial for managing sensitive workflows, and aligns with UiPath's shift toward partner-driven cloud sales. Broader market movements saw the S&P 500 drop 0.67% and the Nasdaq Composite decline 0.84%, with key enterprise software peers Microsoft and ServiceNow also closing lower. Investors are watching to see if local deployments in South Korea translate into consistent cloud revenue growth for UiPath.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
Go toTop